Showing 1211-1220 of 1236 results for "".
- Allergan Donates $300K to Bridge the Gender Gap in STEMhttps://modernaesthetics.com/news/allergan-donates-300k-to-bridge-the-gender-gap-in-stem/2472964/Allergan has pledged $300K to support STEM Education through their partnership with Girls Inc. In addition to the donation, Allergan is also offering mentoring initiatives and resources to educate and empower future female leaders interest
- Revance’s DaxibotulinumtoxinA for Injection Looks Good in Phase 2 Studies of Forehead Lines and Crow’s Feethttps://modernaesthetics.com/news/revances-daxibotulinumtoxina-for-injection-looks-good-in-phase-2-studies-of-forehead-lines-and-crows-feet/2472963/Revance Therapeutics, Inc.’s next-generation neuromodulator product, DaxibotulinumtoxinA, safely and effectively smoothed forehead lines and Crow’s feet with a median duration of 27 weeks in forehead lines and 24 weeks in crow’s feet achieved in at least one treatment group
- Revance to Acquire HintMDhttps://modernaesthetics.com/news/revance-to-aquire-hintmd/2472941/Revance Therapeutics, Inc. has acquired HintMD, a financial technology platform for the aesthetics industry. Revance has agreed to pay HintMD’s shareholders a total of 8.54 million shares of Revance common stock, subject to customary adjustments provided in the acquisition agreeme
- Revance's DAXI Now One Step Closer to FDA Nodhttps://modernaesthetics.com/news/revances-daxi-now-one-step-closer-to-fda-nod/2472849/Revance Therapeutics, Inc. has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar lines. Under
- Revance Appoints Brand Strategist Jill Beraud to Board of Directorshttps://modernaesthetics.com/news/revance-appoints-brand-strategist-jill-beraud-to-board-of-directors/2471899/Jill Beraud is now a member of Revance Therapeutics, Inc.'s Board of Directors. Ms. Beraud brings more than 25 years’ experience building luxury, fashion, beauty, and consumer brands. Ms. Beraud will also chair a newly-formed Revance Brand St
- Drew Barrymore Named First Emsculpt Celebrity Ambassadorhttps://modernaesthetics.com/news/drew-barrymore-named-first-emsculpt-celebrity-ambassador/2471900/Drew Barrymore is Emsculpt's first celebrity ambassador. Through her partnership with Emsculpt, the actress and lifestyle mogul will share her treatment experience and results with media and on her social media channels. Barrym
- Revance Shares Positive Efficacy and Duration Data for RT002https://modernaesthetics.com/news/revance-share-positive-efficacy-and-duration-data-for-rt002/2471986/Revance Therapeutics, Inc.'s long-acting neuromodulator daxibotulinumtoxinA for Injection (RT002) with its proprietary stabilizing excipient peptide technology delivered positive top-line results in alleviating moderate to severe glabellar lines in the SAKURA 3 Phase 3 open-label, long-term s
- Allergan Acquires Bonti for $195Mhttps://modernaesthetics.com/news/allergan-acquires-bonti-for-195m/2472036/Allergan acquired Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications. Following completion of the
- TempSure Vitalia from Cynosure Hits North American Markethttps://modernaesthetics.com/news/tempsure-vitalia-from-cynosure-hits-north-american-market/2472068/Hologic's Cynosure division has launched TempSure™ Vitalia in North America. TempSure Vitalia is an FDA-cleared and Health Canada-approved advanced radiofrequency treatment that delivers therapeutic heat to inter
- Game On: Revance Readies for Launch of their Botox Competitorhttps://modernaesthetics.com/news/game-on-revance-readies-for-launch-of-their-botox-competitor/2472111/With the advent of four new positions, Revance Therapeutics is expanding their commercialization team in anticipation of the product launc